A monk's prayer: O Lord what is the answer to in-stent restenosis? Commentary on the TRAPIST study

European Heart Journal

Volumn 22, Issue 20, 2001, Pages 1847-1849

  Murphy, J G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN; TRAPIDIL;

BRACHYTHERAPY; CLINICAL TRIAL; CORONARY STENT; DRUG EFFECT; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RELEASE; EDITORIAL; ENZYME ACTIVATION; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HUMAN; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; RISK FACTOR; SUDDEN DEATH; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD VESSEL PROSTHESIS IMPLANTATION; COMBINED MODALITY THERAPY; CORONARY RESTENOSIS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; STENTS; TRAPIDIL; TREATMENT OUTCOME; UNITED STATES; VASODILATOR AGENTS;

EID: 0035149961     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2758     Document Type: Editorial

References (7)

1. Trapidil inhibits plateletderived growth factor stimulated mitogen activated protein kinase cascade
2. Trapidil reverses rat vascular smooth muscle cell proliferation in vitro and in vivo
3. Long-term efficacy of intracoronary irradiation in inhibiting in-stent restenosis
4. Edge stenosis and geographical miss following intracoronary gamma radiation therapy for in-stent restenosis
5. The TRAPIST study: A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound
6. Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months
7. Lack of intimal response after implantation of sirolimus-coated stents in human coronary arteries: A QCA and 3-DIVUS study